Gabriel “Gabe” Ortiz: New Director at Artoss, Inc.

Gabe Ortiz, a veteran of the biologics space, is the new director of Sales, Western Region, for Artoss, Inc., based in St. Cloud, Minnesota. Ortiz is responsible for continuing the sales growth of NanoBone Bone Graft in a 13–state region west of the Mississippi River and for identifying, training, and managing independent distributors in that region.

Paul Byerley, managing director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, said, “Gabe has a wealth of experience in building and managing orthobiologic sales organizations. He had nationwide responsibilities as Vice President of Sales for Prosidyan. Prior to that, he spent ten years with Medtronic building and leading the Biologics Organization in the West with sales of Infuse Bone Graft and the complete allograft/synthetic product portfolio. We’re pleased that Gabe recognizes the opportunity to represent the best standalone synthetic graft on the market and welcome him to Artoss.”

“I am very excited to join the well-established and respected executive team of Paul Byerley and Jim Cassidy to continue to drive the tremendous momentum already established in the West.” said Gabe. “I have been in the biologics space for over a decade and never have I seen such an incredible standalone product as NanoBone. I am humbled and honored to work with this team and utilize my extensive leadership experience in the biologics space to continue to take NanoBone to the next level!”

Gabe Ortiz told OTW, “We have a very unique, disruptive technology and ensuring we can get it into the hands of our surgeon customers to ultimately benefit the patients is a key priority.”

“I will be working hard to grow existing business and expand our current distribution network with a solid group of agents and reps. Access is also top priority and I will be utilizing my relationships to gain access in local networks as well as major GPO/IDN networks.”

“Under my leadership, year 1 priorities are to continue to drive local and national approvals, increase our distribution footprint and continue to position NanoBone as a disruptive, best in class Synthetic bone graft, which will ultimately help improve patients’ lives.”